- Home
- NEOV vs ACOG Comparison
NEOV vs ACOG Comparison
Compare NEOV & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- ACOG
- Stock Information
- Founded
- NEOV 2018
- ACOG 2000
- Country
- NEOV United States
- ACOG Canada
- Employees
- NEOV N/A
- ACOG N/A
- Industry
- NEOV Industrial Machinery/Components
- ACOG
- Sector
- NEOV Miscellaneous
- ACOG
- Exchange
- NEOV Nasdaq
- ACOG Nasdaq
- Market Cap
- NEOV 153.9M
- ACOG 129.6M
- IPO Year
- NEOV N/A
- ACOG N/A
- Fundamental
- Price
- NEOV $5.72
- ACOG $7.43
- Analyst Decision
- NEOV Hold
- ACOG Strong Buy
- Analyst Count
- NEOV 1
- ACOG 1
- Target Price
- NEOV N/A
- ACOG $20.00
- AVG Volume (30 Days)
- NEOV 376.6K
- ACOG 89.9K
- Earning Date
- NEOV 11-07-2025
- ACOG 11-14-2025
- Dividend Yield
- NEOV N/A
- ACOG N/A
- EPS Growth
- NEOV N/A
- ACOG N/A
- EPS
- NEOV N/A
- ACOG N/A
- Revenue
- NEOV $8,426,835.00
- ACOG $4,586,341.00
- Revenue This Year
- NEOV $121.51
- ACOG N/A
- Revenue Next Year
- NEOV $32.79
- ACOG $149.89
- P/E Ratio
- NEOV N/A
- ACOG N/A
- Revenue Growth
- NEOV 218.59
- ACOG N/A
- 52 Week Low
- NEOV $1.80
- ACOG $3.75
- 52 Week High
- NEOV $6.11
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- NEOV 64.24
- ACOG 41.71
- Support Level
- NEOV $4.65
- ACOG $6.40
- Resistance Level
- NEOV $5.05
- ACOG $7.62
- Average True Range (ATR)
- NEOV 0.45
- ACOG 0.61
- MACD
- NEOV 0.01
- ACOG -0.03
- Stochastic Oscillator
- NEOV 89.56
- ACOG 39.76
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.